NBCNews.com | Ethicist: Why a New Alzheimer's Drug Isn't A No-Brainer NBCNews.com In a very early stage safety test aducanumab slowed the cognitive decline and dementia associated with Alzheimer's in people. On the Mini Mental Status Exam, a widely used measure of cognitive function, people at risk of Alzheimer's who got a placebo ... Alzheimer's debate revived as Biogen's drug trial advances Potential Alzheimer's drug further backs protein hypothesis |